Immune Pharmaceuticals Inc.’s Acquisition of the rights to Ceplene from Meda A.B.

Pearl Cohen represented Immune Pharmaceuticals Inc. in its transaction to acquire the rights to Ceplene from Meda A.B., now part of Mylan, a global healthcare company. Ceplene, an advanced drug to treat leukemia, has been shown in clinical studies to prevent leukemic relapses in patients in remission.

Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops and commercializes novel targeted therapeutics in the immuno-inflammation and immuno-oncology areas. The company, led by John C. Militello and Monica E. Luchi, is based in New York.

Senior Partner and Chair of the Life Science Practice Group Mark Cohen (Picture), together with Partner Michael Nussbaum from our Corporate and Licensing Group, led the transaction and handled the patent diligence and corporate matters, respectively.

Involved fees earner: Mark Cohen – Pearl Cohen; Michael Nussbaum – Pearl Cohen;

Law Firms: Pearl Cohen;

Clients: Immune Pharmaceuticals, Inc.;


Author: Ambrogio Visconti